Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer

Kevin Martell\textsuperscript{1,2}, Hans Chung\textsuperscript{1}, Gerard Morton\textsuperscript{1}, Danny Vesprini\textsuperscript{1}, Chia-Lin Tseng\textsuperscript{1}, Ewa Szumacher\textsuperscript{1}, Patrick Cheung\textsuperscript{1}, Will Chu\textsuperscript{1}, Stanley Liu\textsuperscript{1}, Andrew Loblaw\textsuperscript{1,3}

\textsuperscript{1}Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; \textsuperscript{2}Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; \textsuperscript{3}Institute for Health Policy, Measurement and Evaluation, University of Toronto, Toronto, ON, Canada

\textbf{Funding:} The project was supported in part by funding from the Department of Radiation Oncology at the University of Toronto.

\textbf{Cite as:} Martell K, Chung H, Morton G, et al. Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer. \textit{Can Urol Assoc J} 2022 March 11; Epub ahead of print. http://dx.doi.org/10.5489/cuaj.7752

Published online March 11, 2022

\textbf{Corresponding author:} Dr. Andrew Loblaw, Sunnybrook Health Sciences Center, Toronto, ON Canada; andrew.loblaw@sunnybrook.ca

***

\textbf{Abstract}

\textbf{Introduction:} We aimed to determine the minimum cross-sectional ellipsoid area on magnetic resonance (MR) of intraprostatic nodules that best predicts for subsequent targeted biopsies revealing $\geq$ grade group (GG) 2 disease.

\textbf{Methods:} Forty-six patients previously diagnosed with GG 1 prostate adenocarcinoma who received cognitively fused, MR-guided, transperineal targeted biopsies in addition to six random biopsies were included in this analysis. A Youden cutpoint analysis was used to determine the ellipsoid area in the axial plane best predicting for $\geq$GG 2 disease within the targeted biopsy cores and logistic regression used to assess the result.

\textbf{Results:} Median time from MR imaging to targeted biopsy was 2.4 (1.4–5.5) months. Forty of 46 (87\%) patients had one nodule and 6/46 (13\%) had two separate nodules on MR that received targeted biopsy. Of the 52 nodules, five (10\%), 33 (63\%), and 14 (27\%) were Prostate Imaging–Reporting and Data System (PI-RADS) 3, 4, and 5. Thirteen (25\%), six (12\%), and 33 (64\%) were in the anterior, medial, and posterior regions of the prostate. Median area was 0.72 (0.49–1.29) cm\textsuperscript{2} (average diameter 9.5 mm). Fifteen of 46 (33\%) patients had $\geq$1 random biopsy and 20/52 (38\%) nodules had $\geq$1 targeted biopsy revealing $\geq$GG 2 disease. The optimal area cutpoint
was $\geq 0.7 \text{cm}^2$, with an area under the curve of 0.671 (0.510–0.832). On logistic regression, areas $\geq 0.7 \text{ cm}^2$ was solely predictive of targeted biopsy revealing $\geq$ GG 2 disease (odds ratio 6.5, 1.3–32.4, p=0.022).

**Conclusions:** Nodule area $\geq 0.7 \text{ cm}^2$ may predict for transperineal-based targeted biopsies being positive for $\geq$ GG 2 disease when 1–2 cores are taken.

**Introduction**
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in North American men.\(^1\) With increasing life expectancy and changes in screening patterns, the incidence of prostate cancer in Canadian men is estimated to double by 2030.\(^2\) Despite recent changes in screening guideline recommendations, over 90% of men are diagnosed with localized disease.\(^3\) Of these, a considerable number of patients are initially diagnosed with low-risk disease after trans-rectal ultrasound guided biopsy. In these patients, active surveillance allows for significant delays in times to treatment and treatment related toxicity without impacting survival outcomes.\(^4\) The outcomes of active surveillance may be dependent on how representative biopsy specimens are of true disease extent. In this regard, randomly sampled trans-rectal ultrasound guided biopsies have been known to under quantify the disease when compared to prostatectomy specimens.\(^5\) Magnetic resonance (MR) imaging guided biopsies have been shown to increase the sensitivity and specificity of transrectal ultrasound (TRUS) guided biopsy for pathologic disease progression.\(^6\) Because of this, use of MR imaging and targeted biopsies of MR nodule(s) is becoming commonplace in patients on active surveillance.\(^7\) Despite this, little is known about the diagnostic accuracy of MR imaging guided biopsies as it relates to nodule size or location within the prostate.

On the assumption that smaller nodules would have a higher probability of geographic miss at the time of biopsy, this study aimed to determine the minimal ellipsoid cross-sectional area on MR (eA), in the plane perpendicular to the biopsy that would be associated with Gleason grade group (GG) 2 or higher disease on targeted biopsy (TBx) specimens.

**Methods**
In this quality assurance study, the electronic medical records were retrospectively reviewed from 95 patients eligible for active surveillance and receiving MR guided transperineal targeted biopsies at a large volume center with considerable expertise in transrectal ultrasound guided procedures between December 2015 and May 2019. Patients were included in review if they had an initial systematic TRUS guided biopsy positive for GG1 disease and went on to have MR imaging then transperineal based, MR to TRUS cognitively fused TBx of the MR nodule(s) and additional transperineal systematic biopsies. In lieu of a formal ethics committee the principles of the Helsinki Declaration were followed.
**Active surveillance and magnetic resonance imaging procedures**

Patients with low risk and selected low volume GG2 prostate cancer patients were recommended active surveillance. Over the study period patients were often offered multi-parametric MR imaging as an alternative to routine repeat biopsy based on previous work from our centre. MRs uniformly included T2, T1 and DWI image sets. Reporting was systematic and incorporated information about T2 signal intensity changes, dynamic contrast enhancement and diffusion restriction with corresponding DWI and ADC map changes according to the prostate imaging and data reporting system (PIRADs). All lesions were measured in the axial plane on T2 image sets for width (left-right dimension), height (ant-post dimension). Measurements of length (superior-inferior dimension) were not routinely reported but when available were based on the sagittal plane on T2 image sets. All nodule(s) were measured independently of one another, and locations were described according to laterality (left gland, right gland), prostate region (apex, mid gland, base) and relative position to the rectum (anterior gland, medial gland, posterior gland). Patients were recommended targeted biopsy when new or changing nodule(s) were identified on MR imaging or nodule(s) were identified that were unlikely to have been sampled at the time of TRUS-guided standard biopsy (e.g. nodules within the anterior prostate gland). PSA changes alone were considered insufficient for recommendation of targeted biopsy.

**Biopsy procedures**

Initial biopsies for all patients were transrectal sextant biopsies using transrectal ultrasound guidance and procedures that are well described elsewhere. In brief, patients consenting to biopsy received prophylactic antibiotics and underwent an enema 2 and 4 hours prior to procedure. Then, within the interventional radiology suite the TRUS probe was inserted. With good visualization of the prostate both left and right (bilateral) apex, mid gland and base were sampled. Biopsies either consisted of 6 or 12 total cores with some 12 core samples being combined according to prostate sextant (i.e. 12 cores submitted as 6 specimens).

For TBx, the institutional standard of transperineal prostate biopsies was adopted. In brief patients were given prophylactic antibiotics and underwent enema at least 2 hours prior to the procedure. They then presented to the procedure suite where, with legs raised in stirrups a trans-rectal ultrasound probe was inserted into the rectum. The perineum was sterilized, and local anesthetic was infiltrated both into the skin surface then into the periprostatic nerve bundles bilaterally under direct ultrasound visualization. Biopsies were then taken systematically from the bilateral anterior, medial, and posterior gland based on both axial and sagittal ultrasound images. TBx were then directed to the region of prostate where MR disease was visualized based on cognitive fusion. Although it varied according to physician practice, most nodules underwent at least two TBx. Physicians performing the biopsies were either radiation oncologists with considerable transperineal based prostate brachytherapy experience or prostate brachytherapy fellows under their direct supervision.
**Pathological reporting**
All specimens underwent routine central review by dedicated genitourinary pathologists. Individual reporting for each sample was accompanied by synoptic reporting with overall GG. For each tissue sample, both GG and percentage of core tissue positive for cancer was available. For initial biopsies (transrectally acquired), individual specimens were recorded according to prostate laterality and region (apex, mid gland, base) in most patients. In some tissue samples were aggregate and only synoptic reporting available. For random biopsies at the time of transperineal TBx, individual specimens were recorded according to prostate laterality and relative position to the rectum (anterior, medial, or posterior gland). TBx were recorded according to the corresponding MR nodule(s) and sample number (e.g. nodule 1, biopsy 2).

**Statistical methods**
The Shapiro-Wilk test of normality was used to determine normality in all variables. Descriptive statistics was used to describe the cohort. Normally distributed variables were described using the mean and standard deviation, and non-normally distributed variables were described using median and inter-quartile-range (IQR). For binomial and ordinal variables, absolute count and percentages were used. For MR nodules, the ellipsoid formula was used to calculate an eA of the nodule in the axial plan (Area = pi*a*b) where “a” is the width/2 and “b” is the height/2 of the lesion. Logistic regression modelling was then employed on the combined cohort of all targets biopsied to determine if pre-specified factors including eA of the nodule (as a continuous variable), number of biopsy cores taken (as a continuous variable), PIRADS score (as an ordinal variable) and nodule location (anterior, medial or posterior; a division that determines biopsy difficulty based on the performing center’s clinical experience; note: all lesions crossing the medial aspect of the gland were considered as having medial disease for this analysis) were predictive of nodule being positive for GG 2 or higher disease (binomial yes/no). Finally, a Youden based area under the receiver operator curve analysis was performed on the eA of the DIL on MRI to determine if a specific cutpoint for DIL eA would be more predictive of biopsy positivity for GG 2 or higher disease. The cutpoint found was then used as a binomial variable and the logistic regression analysis repeated.

**Results**
Between July 2015 and May 2019, a total of 95 patients receiving a total of 101 MRI guided transperineal TBx procedures were identified. Of these, 14 patients did not have an initial non-TBx and were excluded from the primary analysis. A further 14, 6 and 1 patients had no disease, GG 2 and 3 disease on initial non-TBx and were excluded. Finally, a further 14 patients did not have complete systematic biopsies at the time of transperineal TBx and were excluded. Finally, 1 patient remained with two separate TBx procedures. In this case the first TBx procedure was used. This left a final cohort of 46 patients receiving 46 transperineal TBx procedures. Within this cohort 26 patients had an initial transrectal biopsy with detailed initial pathologic reporting a
median of 24 (9-44) months prior to their MR. Their regions of biopsy positivity are described in Table 1.

The median time from MRI to transperineal TBx was 2.4 (1.4-5.5) months. 40 of 46 (87%) had one nodule and 6/46 (13%) patients had two separate nodules identified on MRI that were targeted on transperineal biopsy. Within the 52 nodules that eventually went on to have targeted biopsies, 5 (10%) were PIRADS 3, 33 (63%) were PIRADS 4, and 14 (27%) were PIRADS 5. Median eA of the nodules was 0.72 (0.49-1.29)cm2. The nodule locations are described in Table 2.

Random biopsy results at the time of transperineal TBx are described in Table 3. Overall, 21 (46%) patients were diagnosed with higher grade disease after the transperineal biopsy procedure. Fifteen (32%) patients had at least one random biopsy core positive for GG2 or higher disease at the time of transperineal TBx [11 (24%) had 1 core positive and 4 (9% had 2 cores positive)].

A total of 3 (7%) patients had overall GG3 disease after the TBx procedure (Table 4). 18 (39%), 18 (39%) and 7 (15%) had GG 2, 1 and no disease based on the TBx procedure. A total of 6 (13%) patients had TBx cores with GG 2 or higher disease and either GG 1 or no disease on random biopsy cores.

When considering the 52 targeted biopsies as individual events, a total of 20 (38%) biopsy targets came back as harboring GG2 or higher disease. On logistic regression modelling no factors significantly predicted for targeted biopsies coming back as positive for GG2 or higher disease.

The receiver operator curve analysis revealed a cutpoint of eA > 0.69cm2 as predictive for a DIL biopsy positive for GG2 or higher disease with an area under the curve of 0.671 (0.510-0.832) (Supplemental Figure 1). For this cutpoint, sensitivity was 80%, specificity was 63% and the positive and negative predictive values were 57% and 83% respectively. 28 of 52 (54%) targets had eA ≥ 0.7cm2. 16 of 28 (57%) of targets ≥ 0.7cm2 and 4 of 24 (17%) of targets < 0.7cm2 were positive for GG 2 disease (Fisher’s p=0.004).

The logistic regression analysis was performed again using an eA cutpoint of ≥ 0.7cm2 or < 0.7cm2. Within this model only the eA cutpoint predicted for targeted biopsies coming back as positive for GG2 or higher disease [OR 6.5 (1.3-32.4); p=0.02]. Table 5 shows the regression analyses.

Twenty-eight (51%) of the 55 excluded patients did not have systematic biopsies at the time of targeted biopsy. Retrospectively, their MRI and targeted biopsy results were reviewed. In these patients, the median time from MRI to transperineal TBx was 1.6 (1.3-2.1) months. 20 of 28 (71%) patients had one nodule and 8/28 (29%) had two separate nodules identified on MRI that were targeted on transperineal biopsy. Within the 36 nodules that eventually went on to have targeted biopsies, 8 (22%) were PIRADS 3, 15 (42%) were PIRADS4 and 13 (36%) were PIRADS 5. Median eA of the nodules was 1.02 (0.59-1.52)cm2 on MRI. On these targeted
biopsies, 11 (31%) specimens were negative for disease, 14 (39%) harbored GG1 disease, 9 (25%) harbored GG2 disease and 2 (6%) harbored GG3 disease. Within these nodules median number of cores taken from each target was 2 (2-3), median number of targeted cores positive was 1 (0-2) and median percentage of targeted biopsy tissue positive was 20 (0-60)%.

When considering the 25 (69%) targets within this cohort with eA ≥0.7cm², 9 (36%) harbored GG2 or higher disease. When considering the 11 (31%) targets within this cohort with eA <0.7cm², 2 (18%) harbored GG2 or higher disease.”

Discussion
This retrospective analysis of targeted transperineal biopsies based on cognitive fusion between MR imaging and real-time ultrasound at the time of biopsy confirmed a positive association between the area of nodule calculated as an ellipsoid in the plane perpendicular to biopsy and the likelihood of biopsy specimens harboring GG2 or higher disease. The finding that nodules ≥0.7cm² were more likely to harbor clinically significant disease is novel and if validated in future studies performed at other centers would guide clinical practice.

With an increasing role for MR imaging with or without MR targeted biopsies in the active surveillance based management of prostate cancer, there will be an increasing emphasis on defining MR features that predict for clinically relevant disease.7,14,15 Despite its intuitive nature, as smaller nodules would theoretically be less likely to be accurately targeted on biopsy, to date this is the first study that correlates MR nodule size with TBx results. Of note, several studies have examined the relationship between prostatectomy specimens and MR findings.16,17 In one notable study Kim et al. found that both tumors >1cm³ and tumors harboring GG2 or higher disease were more likely to correlate with abnormal MR imaging.16 Although it is difficult to compare with the present study given the difference in approach and methodology, there is agreement in nodule size correlating with clinically significant disease with ≥0.7cm² eA having higher rates of disease. Furthermore, within the present study, the overall detection rate of disease that would change management recommendations (≥GG2 disease) was not insignificant. Overall, 46% of patients had GG2 or higher disease after transperineal biopsy. 13% of patients had GG2 or higher disease detected solely on the bases of targeted biopsies. These rates are similar to those reported by Recabal et al (35% of men diagnosed with higher grade disease based on TBx).18 In the present cohort, it is possible that patients upstaged based on systematic biopsies alone could be due to physicians’ adherence to random transperineal biopsy sampling methodology. Specifically, it is possible that regional systematic cores were either consciously or subconsciously focused towards areas nearby the known MR nodules. This possibility seems to be supported by the results of Elkhoury et al. where the detection of ≥GG2 prostate cancer were 15%, 47% and 60% in biopsy naïve patients receiving systematic biopsy only, TBx only or targeted and systematic biopsies respectively.19

Perhaps the largest potential implication for the present study is the potential impact on MR based active surveillance programs.20,21 Although the ASIST study was notably negative in finding utility for MR imaging based TBx in addition to systematic biopsy, this was importantly
a study of patients who were undergoing repeat biopsy as part of their surveillance protocol.\textsuperscript{21} Many clinicians consider MR changes as an indication for repeat biopsy in patients already on active surveillance (as is the practice at the study institution). In this paradigm, the current study holds considerable value as it suggests that the utility of biopsy is limited when small MR nodules are detected. These findings suggest that MR based active surveillance protocols that utilize nodule size and/or other features could be made that maximize the odds of detecting clinically relevant disease. Hence future study and validation of these results is warranted as they may allow future patients to avoid unnecessary repeat biopsies.

There are several limitations to the present study that necessitate the need for validation and future study. The first of these is the small cohort size (46 patients) and retrospective nature. Furthermore, the study center is a quaternary cancer center that sees a high volume of patients and the physicians performing the biopsy procedures have considerable transperineal prostate procedural experience. The same target positivity rates may not be achieved by physicians with less experience or comfort with transperineal procedures. Beyond this, the use of MR fusion software could lead to differences in targeting accuracy and results that differ from the present study. Otherwise, this study is not translatable to transrectal biopsies given the nature of the calculated cross-sectional area. However, if calculated in the superior/inferior and left/right dimensions it may be possible to apply the present result. Finally, the number of targeted biopsies was limited to two samples of most nodules, these results may not be applicable for cases where 5 or 6 targeted biopsies are obtained.

**Conclusions**

In summary, in this retrospective analysis of transperineal targeted biopsies of MR identified nodules cognitively fused to real time ultrasound images, nodules with ellipsoid area $\geq 0.7\text{cm}^2$ in the plane perpendicular to the biopsy (the axial plane) were more likely to be positive for grade group 2 or higher disease when 1-2 cores were taken.
References

1. Smith L, Bryan S, De P, et al. Canadian Cancer Statistics: A 2018 special report on cancer incidence by stage. Canadian Cancer Society. http://cancer.ca/statistics. Published 2018.
2. Bromfield G, Dale D, De P, et al. Canadian cancer statistics 2015 - predictions of the future burden of cancer in Canada. Can Cancer Soc 2015:1-151.
3. Berkowitz Z, Li J, Richards TB, Marcus PM. Patterns of Prostate-Specific Antigen Test Use in the U.S., 2005–2015. Am J Prev Med 2017;53(6):909-13.
4. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33(3):272-7.
5. Cam K, Yucel S, Turkeri L, Akdas A. Accuracy of transrectal ultrasound guided prostate biopsy: Histopathological correlation to matched prostatectomy specimens. Int J Urol 2002;9(5):257-60.
6. Frye TP, George AK, Kilchevsky A, et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. J Urol 2017;197(3 Pt 1):640-6.
7. Stavrinides V, Giganti F, Emberton M, Moore CM. MRI in active surveillance: a critical review. Prostate Cancer Prostatic Dis 2019;22(1):5-15.
8. Mohler J, Antonarakis E, Armstron A, et al. NCCN clinical practice guidelines in oncology - prostate cancer. NCCN Clinical Practice Guidelines in Oncology Version. www.nccn.org. Accessed October 1, 2021.
9. Da Rosa MR, Milot L, Sugar L, et al. A prospective comparison of MRI-US fused targeted biopsy versus systematic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging 2015;41(1):220-5.
10. Venkatesan AM, Stafford RJ, Duran C, Soni PD, Berlin A, McLaughlin PW. Prostate magnetic resonance imaging for brachytherapists: Diagnosis, imaging pitfalls, and post-therapy assessment. Brachytherapy 2017;16(4):688-97.
11. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159(2):471-5; discussion 475-6.
12. Stefanova V, Buckley R, Flax S, et al. Transperineal prostate biopsies under local anesthetic: Experience with 1287 patients Prostate cancer detection rate, complications and patient tolerability Authors. J Urol 2019;201(6):1121-6.
13. Pepdjonovic L, Tan GH, Huang S, et al. Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol 2017;35(8):1199-1203.
14. Fascelli M, George AK, Frye T, Turkbey B, Choyke PL, Pinto PA. The Role of MRI in Active Surveillance for Prostate Cancer. Curr Urol Rep 2015;16(6):42.
15. Drost F-JH, Osses DF, Nieboer D, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev April 2019.
16. Kim JY, Kim SH, Kim YH, Lee HJ, Kim MJ, Choi MS. Low-risk prostate cancer: The
accuracy of multiparametric MR imaging for detection. *Radiology* 2014;271(2):435-44.

17. Alqahtani S, Wei C, Zhang Y, et al. Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system. *Sci Rep* 2020;10(1):1-9.

18. Recabal P, Assel M, Sjoberg DD, et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance. *J Urol* 2016;196(2):374-81.

19. Elkhoury FF, Felker ER, Kwan L, et al. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. *JAMA Surg* 2019;154(9):811-8.

20. Gallagher KM, Christopher E, Cameron AJ, et al. Four-year outcomes from a multiparametric magnetic resonance imaging (MRI)-based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies. *BJU Int* 2019;123(3):429-38.

21. Klotz L, Loblaw A, Sugar L, et al. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. *Eur Urol* 2019;75(2):300-9.
Figures and Tables

### Table 1. Initial (at diagnosis) non-targeted trans-rectal biopsy characteristics for cohort of 26 patients with detailed pathological reporting in the included cohort and 23 patients with detailed pathologic reporting in the excluded cohort.

|                        | Number of patients (%) n=26 | Median (IQR) of positive patients | Number of excluded patients (%) n=23 | Median (IQR) of positive excluded patients |
|------------------------|-----------------------------|-----------------------------------|-------------------------------------|-------------------------------------------|
| Left apex tissue positive | 12 (46%)                    | 5 (4–20)                          | 7 (30%)                             | 15 (5–20)                                 |
| Left mid-tissue positive | 7 (27%)                     | 20 (5–30)                         | 6 (26%)                             | 10 (5–20)                                 |
| Left base tissue positive | 8 (31%)                     | 20 (8–35)                         | 5 (22%)                             | 25 (20–30)                                |
| Right apex tissue positive | 14 (54%)                    | 9 (5–30)                          | 7 (30%)                             | 20 (15–30)                                |
| Right mid-tissue positive | 4 (15%)                     | 10 (2–20)                         | 6 (26%)                             | 15 (10–20)                                |
| Right base tissue positive | 7 (27%)                     | 22 (10–40)                       | 6 (26%)                             | 15 (10–20)                                |

Values are count data (%) for the cohort and median (interquartile range [IQR]) of percentage of positive tissue in those with zone biopsies positive. For example, in the 12 patients with left apex tissue positive, median percentage of core positivity was 5 (4–20)%.

### Table 2. Nodule locations on MR imaging

| No Other | AA | AM | AP | MA | MM | MP | BA | BM | BP |
|----------|----|----|----|----|----|----|----|----|----|
| AA       | 4  (8%) | –  | –  | –  | –  | –  | –  | –  | –  |
| AM       | 1  (2%) | –  | –  | –  | –  | –  | –  | –  | –  |
| AP       | 10 (20%) | – | –  | –  | –  | –  | –  | –  | –  |
| MA       | 2  (4%) | 3  (6%) | – | –  | –  | –  | –  | –  | –  |
| MM       | 2  (4%) | –  | –  | –  | –  | –  | –  | –  | –  |
| MP       | 14 (27%) | 3  (6%) | 1  (2%) | – | –  | –  | –  | –  | –  |
| BA       | 1  (2%) | 3  (6%) | –  | –  | –  | –  | –  | –  | –  |
| BM       | –  | –  | –  | 1  (2%) | –  | –  | –  | –  | –  |
| BP       | 3  (6%) | –  | –  | 3  (6%) | 1  (2%) | –  | –  | –  | –  |

AA: apex anteriorly; AM: apex medially; AP: apex posteriorly; BA: base anteriorly; BM: base medially; BP: base posteriorly; MA: mid-gland anteriorly; MM: mid-gland medially; MP: mid gland posteriorly.
Table 3. Overall biopsy (random biopsy and targeted biopsy) and random biopsy (RBx) results at the time of targeted biopsy (TBx) for 46 patients receiving targeted transperineal biopsies

|                          | Number of Patients (%) | Median (IQR) of positive patients | GG 1 n (%) | GG 2 n (%) | GG 3 n (%) | GG 4 n (%) |
|--------------------------|------------------------|-----------------------------------|-------------|-------------|-------------|-------------|
| Any RBx or TBx positive  | 39 (85%)               | 8 (5–15)                          | 18 (39%)    | 18 (39%)    | 3 (7%)      | 0 (0%)      |
| Any ant RBx positive     | 22 (48%)               | 3 (1–8)                           | 15 (33%)    | 5 (11%)     | 1 (2%)      | 1 (2%)      |
| Any med RBx positive     | 20 (43%)               | 5 (2–7)                           | 14 (30%)    | 3 (7%)      | 3 (7%)      | 0 (0%)      |
| Any post-RBx positive    | 20 (43%)               | 5 (2–8)                           | 14 (30%)    | 5 (11%)     | 1 (2%)      | 0 (0%)      |
| Left ant RBx positive    | 13 (28%)               | 20 (10–40)                        | 10 (22%)    | 2 (4%)      | 1 (2%)      | 0 (0%)      |
| Left med RBx positive    | 12 (26%)               | 20 (7–30)                         | 7 (15%)     | 3 (7%)      | 2 (4%)      | 0 (0%)      |
| Left post-RBx positive   | 11 (24%)               | 10 (5–50)                         | 7 (15%)     | 3 (7%)      | 1 (2%)      | 0 (0%)      |
| Right ant RBx positive   | 16 (35%)               | 10 (5–40)                         | 12 (26%)    | 3 (7%)      | 0 (0%)      | 1 (2%)      |
| Right med RBx positive   | 14 (30%)               | 13 (5–40)                         | 13 (28%)    | 0 (0%)      | 1 (2%)      | 0 (0%)      |
| Right post-RBx positive  | 16 (35%)               | 30 (10–50)                        | 14 (30%)    | 2 (4%)      | 0 (0%)      | 0 (0%)      |

Values are given as median (interquartile range) or number (%) as appropriate.
Table 5. Rank discrimination indices and OR for each factor explored on logistic regression analysis

|                          | eA used as a continuous variable | eA cutpoint of ≥0.7cm² used |
|--------------------------|----------------------------------|-----------------------------|
| Somer’s D                | 0.55                             | 0.64                        |
| eA [cm²] [0.49 vs. 1.27] or [≥0.7 vs. <0.7] | 1.3 (0.5–3.2, p=0.64) | 6.5 (1.3–32.4, p=0.02) |
| Number of targeted biopsies [2 vs. 1] | 0.5 (0.2–1.4, p=0.19) | 0.5 (0.2–1.3, p=0.16) |
| PIRADS score [5 vs. 3]   | 22.3 (0.8–592.5, p=0.06)         | 9.7 (0.7–138.5, p=0.09)   |
| Nodule location [A vs. P] | 0.5 (0.1–3.4, p=0.23) | 0.5 (0.1–2.6, p=0.14) |
| Nodule location [M vs. P] | 2.3 (0.4–14.8, p=0.457)          | 3.0 (0.4–22.4, p=0.4)     |

Data are presented as either the rank discrimination index or the odds ratio (OR) (95% confidence interval of the estimate, p-value).